Cenk Kig

Cenk Kig

Auto-generated profile, based on publicly available information

Cenk Kig

Istanbul University, Faculty of Science, Department of Molecular Biology and Genetics, 34134, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Protoplasma
Verified
Journal Article
Closed access
PDF file
CKCenk Kig
Cenk Kig
GTGuler Temizkan
Guler Temizkan

1 January 2005 in Bioscience, Biotechnology, and Biochemistry
Verified
Journal Article
Closed access
CKCenk Kig
Cenk Kig
STSezai Turkel
Sezai Turkel
GTGüler Temizkan
Güler Temizkan
We have isolated 14 different Schizosaccharomyces pombe mutants that synthesize invertase enzyme constitutively. Analyses of invertase activities revealed that the degrees of resistance to glucose repression were not similar among different complementation groups. One of the complementation groups appeared to be associated with functional and/or regulatory defects in hexose transport. Another complementation group appeared to be specific for the regulation of the inv1 gene alone, implying that these mutations might be associated with different genes acting on the glucose sensing and signaling pathway. In addition, we found that the wild-type level glucose uptake is essential for the full-level repression of inv1 expression.

20 April 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GGGül İpek Gündoğan
Gül İpek Gündoğan
CKCenk Kig
Cenk Kig
MKMeriç Karacan
Meriç Karacan
HDHüsniye Doğruman
Hüsniye Doğruman
Objectives: Dehydroepiandrosterone (DHEA) is an endogenous hormone that acts as a ligand for several cellular receptors. An age-dependent decline in circulating levels of DHEA is linked to changes in various physiological functions. In gynecological clinical practice, DHEA is commonly prescribed to induce ovulation. Some clinical studies report a positive association between high serum concentrations of DHEA and an increased risk of developing ovarian cancer. However, the in vitro physiological effects of DHEA on ovarian cancerous cells have not been explored thus far. In this study, we aimed to investigate the physiological effects of DHEA treatment (0-200 mu M, 24-72 hours) on MDAH-2774 human ovarian cancer cell line and primary HuVeC human endothelial cells. Materials and Methods: The physiological effects of DHEA treatment (0-200 mu M, 24-72 hours) on MDAH-2774 human ovarian cancer cell line and primary HuVeC human endothelial cells were investigated with the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) test, acridine orange/ethidium bromide staining, and scratch assay. Results: DHEA treatment promoted proliferation of the MDAH-2774 cancer cell line in a dose-dependent manner (r=0.6906, p<0.0001, for 24 hours) (r=0.6802, p<0.0001, for 48 hours) (r=0.7969, p<0.0001, for 72 hours). In contrast, DHEA inhibited proliferation of the primary HuVeC cells (r=0.9490, p<0.0001, for 24 hours) (r=0.9533, p<0.0001, for 48 hours) (r=0.9584, p<0.0001, for 72 hours). In agreement with these observations, DHEA treatment resulted in a dose-dependent increase in the number of necrotic cells in the primary HuVeC cells (r=0.97, p<0.0001). However, the number of necrotic or apoptotic cells did not change significantly when the MDAH-2774 cells was exposed to DHEA. Moreover, we found that DHEA treatment reduced the migration rate of HuVeC cells in a dose-dependent manner (r=0.9868, p<0.0001), whereas only a slight increase was observed in the MDAH-2774 ovarian cancer cell line (r=0.8938, p<0.05). Conclusion: Our findings suggest that DHEA promotes the proliferation of ovarian cancer cells in a dose-dependent manner in vitro. Moreover, DHEA induced necrosis and inhibited proliferation in endothelial cells. Although mechanistic evidence is required, our preliminary findings imply that exposure to high doses of DHEA may be associated with an increased risk of developing ovarian cancer.

12 June 2021 in Biologia
Verified
Journal Article
Closed access
PDF file
CKCenk Kig
Cenk Kig
EMElif Mertoglu
Elif Mertoglu
ACAlper Caliskan
Alper Caliskan
HAHizlan Hincal Agus
Hizlan Hincal Agus
EUEvren Önay Uçar
Evren Önay Uçar
VGVarol Güler
Varol Güler

20 April 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AKAhmet Hamdi Kepekçi
Ahmet Hamdi Kepekçi
GGGül İpek Gündoğan
Gül İpek Gündoğan
CKCenk Kig
Cenk Kig
Betahistine is a histamine analog commonly prescribed for symptomatic treatment of vertiginous symptoms. In vitro studies have shown that betahistine was not toxic at the prescribed doses in a nasal epithelial cell line. However, the effect of betahistine on other cell types has not been studied. In this study, we aimed to investigate some of the physiological effects of betahistine on L929 fibroblast, A549 lung cancer, human umbilical vein endothelial (HUVEC), and Ishikawa endometrial cell lines. Cellular proliferation was assed assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, apoptosis was evaluated by acridine orange-ethidium bromide staining, and cellular migration was assed assessed by scratch assay. Betahistine treatment (0.1-0.5 mg/mL, 24 hours) can inhibit cell proliferation and induce apoptosis in HUVEC, A549, Ishikawa, and L929 cell lines. Betahistine (≥0.1 mg/mL) significantly increased the number of apoptotic cells (HUVEC: 26.3%, A549: 17.3%, L929: 8.6%, and Ishikawa: 2.3%). Betahistine at doses over 0.1 mg/mL significantly suppressed the cell migration rate in all of the cell lines. In contrast, exposure to a low dose of betahistine (0.025 mg/mL) induced migration rates of HUVEC and Ishikawa cells by 81% and 48%, respectively. Betahistine may alter the processes of cellular proliferation, apoptosis, and cellular migration in a cell line- and dose-dependent manner. In this sense, proliferative and metastatic properties of certain cancer cells can potentially be altered in response to betahistine treatment.

18 July 2021 in Australian Endodontic Journal
Verified
Journal Article
Closed access
PDF file
GGGül İpek Gündoğan
Gül İpek Gündoğan
SDSare Durmus
Sare Durmus
GOGulgun Cansu Ozturk
Gulgun Cansu Ozturk
NKNazmi Kucukyesil
Nazmi Kucukyesil
YAYasin Talat Acar
Yasin Talat Acar
CKCenk Kig
Cenk Kig